Literature DB >> 26546158

Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.

Yizhen Li1, Huanwei Wang1, Xiaoling Wang1, Wen Jin1, Yun Tan1, Hai Fang2, Saijuan Chen3, Zhu Chen4, Kankan Wang4.   

Abstract

The AML1/ETO fusion protein is essential to the development of t(8;21) acute myeloid leukemia (AML) and is well recognized for its dominant-negative effect on the coexisting wild-type protein AML1. However, the genome-wide interplay between AML1/ETO and wild-type AML1 remains elusive in the leukemogenesis of t(8;21) AML. Through chromatin immunoprecipitation sequencing and computational analysis, followed by a series of experimental validations, we report here that wild-type AML1 is able to orchestrate the expression of AML1/ETO targets regardless of being activated or repressed; this is achieved via forming a complex with AML1/ETO and via recruiting the cofactor AP-1 on chromatin. On chromatin occupancy, AML1/ETO and wild-type AML1 largely overlap and preferentially bind to adjacent and distinct short and long AML1 motifs on the colocalized regions, respectively. On physical interaction, AML1/ETO can form a complex with wild-type AML1 on chromatin, and the runt homology domain of both proteins are responsible for their interactions. More importantly, the relative binding signals of AML1 and AML1/ETO on chromatin determine which genes are repressed or activated by AML1/ETO. Further analysis of coregulators indicates that AML1/ETO transactivates gene expression through recruiting AP-1 to the AML1/ETO-AML1 complex. These findings enrich our knowledge of understanding the significance of the interplay between the wild-type protein and the oncogenic fusion protein in the development of leukemia.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26546158     DOI: 10.1182/blood-2015-03-626671

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

2.  Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.

Authors:  Chun Guo; Jian Li; Nickolas Steinauer; Madeline Wong; Brent Wu; Alexandria Dickson; Markus Kalkum; Jinsong Zhang
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

Review 3.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

4.  Definition of a small core transcriptional circuit regulated by AML1-ETO.

Authors:  Kristy R Stengel; Jacob D Ellis; Clare L Spielman; Monica L Bomber; Scott W Hiebert
Journal:  Mol Cell       Date:  2020-12-30       Impact factor: 17.970

5.  Developmental Control of NRAMP1 (SLC11A1) Expression in Professional Phagocytes.

Authors:  Mathieu F M Cellier
Journal:  Biology (Basel)       Date:  2017-05-03

6.  LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML.

Authors:  Qian Chen; Murat A Cevher; Qi Jiang; Saisai Wang; Xiaojian Sun; Robert G Roeder; Mo Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-10       Impact factor: 12.779

7.  Construction of ssDNA-Attached LR-Chimera Involving Z-DNA for ZBP1 Binding Analysis.

Authors:  Lin Li; Ran An; Xingguo Liang
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

8.  Nuclear export of chimeric mRNAs depends on an lncRNA-triggered autoregulatory loop in blood malignancies.

Authors:  Zhen-Hua Chen; Tian-Qi Chen; Zhan-Cheng Zeng; Dan Wang; Cai Han; Yu-Meng Sun; Wei Huang; Lin-Yu Sun; Ke Fang; Yue-Qin Chen; Xue-Qun Luo; Wen-Tao Wang
Journal:  Cell Death Dis       Date:  2020-07-23       Impact factor: 8.469

9.  Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning.

Authors:  Zhi Guo; Chen Xu; Hu Chen
Journal:  Oncotarget       Date:  2017-11-03

10.  ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.

Authors:  Jean-Baptiste Micol; Alessandro Pastore; Daichi Inoue; Nicolas Duployez; Eunhee Kim; Stanley Chun-Wei Lee; Benjamin H Durham; Young Rock Chung; Hana Cho; Xiao Jing Zhang; Akihide Yoshimi; Andrei Krivtsov; Richard Koche; Eric Solary; Amit Sinha; Claude Preudhomme; Omar Abdel-Wahab
Journal:  Nat Commun       Date:  2017-05-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.